Impel NeuroPharma, Inc. is a late-stage pharmaceutical company that utilizes its proprietary Precision Olfactory Delivery (POD®) technology to develop and commercialize transformative therapies for people suffering from diseases with high unmet needs, with an initial focus on diseases of the central nervous system (CNS). As the first company to investigate targeting the upper nasal space with optimized therapeutic molecules and formulations for CNS diseases, Impel has pioneered an approach to drug delivery that has the potential to provide rapid relief following symptomatic onset. In addition to Trudhesa™ (dihydroergotamine mesylate) nasal spray, which is approved in the United States for the acute treatment of migraine with or without aura in adults, Impel is developing INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson’s disease.